Singer F R, Aldred J P, Neer R M, Krane S M, Potts J T, Bloch K J
J Clin Invest. 1972 Sep;51(9):2331-8. doi: 10.1172/JCI107044.
21 patients with Paget's disease of bone and one with osteoporosis were studied to detect development of antibodies to salmon calcitonin during chronic therapy. Antibody titers ranged from 1:40 to 1:30,000 in plasma obtained after treatment of 11 patients. Radio-immunoelectrophoresis revealed that the antibodies were restricted to the gammaG class. One patient, W. O., with Paget's disease initially responded to treatment with a decrease in bone turnover, but later became resistant to the hormone in association with the appearance of a very high titer (1:30,000) of antibody against salmon calcitonin. A 1:10 dilution of his plasma was shown to completely inactivate 20 mMRC units/ml of salmon calcitonin as detected by bioassay in rats; slight inactivation was detected at a 1:200 dilution. All other patients continued to respond to salmon calcitonin despite the development of antibody to the hormone in ten cases. No evidence of systemic allergic reactions or other toxicity was found in any patient. The data suggest that although antibody formation may occur in as many as 50% of patients treated with salmon calcitonin, this antibody response is unlikely to be of clinical significance in most patients. However, in an occasional patient, a marked antibody response may occur which interferes with the therapeutic use of the hormone.
对21例骨Paget病患者和1例骨质疏松症患者进行了研究，以检测慢性治疗期间抗鲑鱼降钙素抗体的产生情况。在11例患者治疗后获得的血浆中，抗体滴度范围为1:40至1:30,000。放射免疫电泳显示，抗体仅限于γG类。1例患有Paget病的患者W.O.最初对治疗有反应，骨转换率下降，但后来对该激素产生耐药性，同时出现了非常高滴度（1:30,000）的抗鲑鱼降钙素抗体。通过大鼠生物测定法检测发现，其血浆1:10稀释液可使20mRC单位/毫升的鲑鱼降钙素完全失活；在1:200稀释时检测到轻微失活。尽管10例患者产生了针对该激素的抗体，但所有其他患者继续对鲑鱼降钙素产生反应。在任何患者中均未发现全身过敏反应或其他毒性的证据。数据表明，尽管在用鲑鱼降钙素治疗的患者中多达50%可能会出现抗体形成，但这种抗体反应在大多数患者中不太可能具有临床意义。然而，偶尔会有患者出现明显的抗体反应，从而干扰该激素的治疗应用。
